Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...